Type 2 Diabetes Program:
General Safety Profile (AEs in ³ 2%* of
Rimonabant-treated Patients)
Type 2 Diabetes
Program: General Safety Profile (AEs in 2%* of Rimonabant-treated Patients)
Rimonabant 20 mg was
evaluated specifically in patients with type 2 diabetes in the RIO Diabetes
study (a 1-year study in overweight or obese type 2 diabetes patients already
receiving oral antidiabetic medication) and in the SERENADE study (drug-naïve
type 2 diabetes patients recruited irrespective of weight status and randomly
assigned to rimonabant 20 mg or placebo for 6 months).This slide shows the tolerability and
safety profile of rimonabant pooled from these two studies.
The pattern and
frequency of adverse events in this type 2 diabetic population were similar
to the pattern and frequency of adverse events observed in the overall pooled
RIO trial population described in the previous slide.